Education
About Us
Working with TipRanks
Follow Us
China NT Pharma Group Co., Ltd. (HK:1011)
:1011
1011 Stock Chart & Stats
HK$0.84
<HK$0.01(0.40%)
At close: 4:00 PM EST
HK$0.84
<HK$0.01(0.40%)
Day’s Range― - ―
52-Week RangeHK$0.19 - HK$1.35
Previous CloseN/A
Volume22.00K
Average Volume (3M)1.68M
Market Cap
HK$505.68M
Enterprise ValueHK$758.81M
Total Cash (Recent Filing)HK$4.63M
Total Debt (Recent Filing)HK$316.72M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Mar 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding674,246,030
10 Day Avg. Volume1,250,790
30 Day Avg. Volume1,683,352
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-0.17
Price to Sales (P/S)1.76
P/FCF Ratio-7.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified Revenue StreamsSelling through hospitals, pharmacies and direct OTC channels creates multiple revenue engines and reduces reliance on any single buyer type. This distribution diversity supports steadier demand and resilience to localized disruptions, a durable benefit for cash generation over months.
R&D And Innovation FocusA strategic emphasis on innovative drug development positions the company to move up the value chain from generics to proprietary therapies. Success in R&D can drive sustainable revenue, higher margins and licensing opportunities, making this a structural positive if execution continues.
Therapeutic BreadthParticipation across multiple therapeutic areas diversifies clinical and commercial risk, enabling cross-selling and pipeline flexibility. A broad therapeutic footprint increases long-term market opportunity and reduces dependency on any single product or indication.
Bears Say
Negative Shareholders' EquityNegative equity is a structural solvency flag that constrains capital-raising options, creditor confidence and strategic flexibility. Persistent negative equity increases insolvency risk over months and can limit ability to fund R&D, operations, or absorb shocks without dilutive financing.
Sustained Losses And Revenue DeclineOngoing net losses and falling revenue undermine internal financing capacity and long-term profitability. Without a clear path to consistent positive EBIT, the firm may struggle to invest in growth, retain talent, or compete effectively, impairing durable business prospects.
Erratic Operating Cash FlowInconsistent operational cash generation and a sharp free cash flow decline create recurring liquidity pressure, forcing reliance on external funding. Over several months this raises refinancing and covenant risks, restricting strategic options and threatening continuity of R&D and commercialization.
China NT Pharma Group Co., Ltd. News
1011 FAQ
What was China NT Pharma Group Co., Ltd.’s price range in the past 12 months?
China NT Pharma Group Co., Ltd. lowest stock price was HK$0.19 and its highest was HK$1.35 in the past 12 months.
What is China NT Pharma Group Co., Ltd.’s market cap?
China NT Pharma Group Co., Ltd.’s market cap is HK$505.68M.
When is China NT Pharma Group Co., Ltd.’s upcoming earnings report date?
China NT Pharma Group Co., Ltd.’s upcoming earnings report date is Mar 26, 2026 which is in 32 days.
How were China NT Pharma Group Co., Ltd.’s earnings last quarter?
China NT Pharma Group Co., Ltd. released its earnings results on Aug 08, 2025. The company reported -HK$0.032 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.032.
Is China NT Pharma Group Co., Ltd. overvalued?
According to Wall Street analysts China NT Pharma Group Co., Ltd.’s price is currently Overvalued.
Does China NT Pharma Group Co., Ltd. pay dividends?
China NT Pharma Group Co., Ltd. pays a Annually dividend of HK$0.035 which represents an annual dividend yield of N/A. See more information on China NT Pharma Group Co., Ltd. dividends here
What is China NT Pharma Group Co., Ltd.’s EPS estimate?
China NT Pharma Group Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does China NT Pharma Group Co., Ltd. have?
China NT Pharma Group Co., Ltd. has 674,246,030 shares outstanding.
What happened to China NT Pharma Group Co., Ltd.’s price movement after its last earnings report?
China NT Pharma Group Co., Ltd. reported an EPS of -HK$0.032 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.282%.
Which hedge fund is a major shareholder of China NT Pharma Group Co., Ltd.?
Currently, no hedge funds are holding shares in HK:1011
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
China NT Pharma Group Co., Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
113.15%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
3.66%
Trailing 12-Months
Company Description
China NT Pharma Group Co., Ltd.
China NT Pharma Group Company Limited, together with its subsidiaries, engages in the research and development, manufacturing, sales, and distribution of pharmaceutical products in the People's Republic of China and internationally. It manufactures, sells, and trades in prescription medicines for the tumor and blood system diseases, digestive system diseases, central nervous system diseases, diseases of respiratory system, and other therapeutic fields; and produces and sells NT branded products and generic drugs. The company also provides marketing and promotion services to suppliers, and logistics and consulting services. China NT Pharma Group Company Limited was founded in 1995 and is headquartered in Suzhou, the People's Republic of China.
Technical Analysis
Tianda Pharmaceuticals Ltd.
―
Wai Yuen Tong Medicine Holdings Limited
―
Fusen Pharmaceutical Co., Ltd.
―
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H
―
Huakang Biomedical Holdings Company Limited
―